Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Co-Diagnostics, Inc. (CODX)

Co-Diagnostics to host investor presentation on ReadyGo collaboration and Co-Dx PCR platform

Neutral Impact 2 of 5 other Written later

Co-Diagnostics, Inc. filed an 8-K stating it will host an investor and analyst presentation on September 16, 2026, covering its collaboration with ReadyGo Diagnostics Ltd., the Co-Dx PCR platform, manufacturing initiatives, and operations in India. The filing contains no financial results, guidance, or new transaction terms; the presentation materials are furnished as Exhibit 99.1.

Key points

  • Investor and analyst presentation scheduled for September 16, 2026
  • Topics include the ReadyGo Diagnostics Ltd. collaboration and the Co-Dx PCR platform
  • Presentation materials furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
  • Filing signed by CEO Dwight Egan

The filing

CompanyCo-Diagnostics, Inc. (CODX)
Form8-K, current report
Filed with the SECSep 16, 2026, 10:30 AM ET
Accession number0001493152-26-042854

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.